Validation of the prediction score for inhibitor development in previously untreated patients (PUPs) with severe hemophilia A

被引：0
|
作者：
Hashemi, S. [1 ,2 ,3 ]
Fischer, K. [1 ,2 ]
Van den Berg, H. [3 ]
机构：
[1] UMC Utrecht, Dept Creveldklin & Hematol, Utrecht, Netherlands
[2] UMC Utrecht, Julius Ctr Hlth Sci, Utrecht, Netherlands
[3] UMC Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands
来源：
HAEMOPHILIA | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [11] Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: The RODIN study
    Gouw, S.
    Van den Berg, H.
    Van der Bom, J.
    HAEMOPHILIA, 2012, 18 : 89 - 89
  • [12] Inhibitors in previously untreated patients (PUPS) with severe hemophilia A: a follow-up cohort study
    Mancuso, M. E.
    van den Berg, H. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 846 - 846
  • [13] Validation of the prediction model for inhibitor development in PUPs with severe haemophilia A
    Hashemi, S. M.
    Fischer, K.
    Moons, K. G. M.
    van den Berg, H. M.
    HAEMOPHILIA, 2016, 22 (02) : E116 - E118
  • [14] Exploration of biomarkers for early recognition of FVIII inhibitor development in previously untreated severe hemophilia A patients: Hemophilia Inhibitor PUP Study and beyond
    Hofbauer, C. J.
    Male, C.
    Brown, D.
    Santagostino, E.
    Oldenburg, J.
    Scheiflinger, F.
    Reipert, B. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 133 - 133
  • [15] Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia B
    Shapiro, A
    Abshire, T
    Gill, J
    Kisker, T
    Pasi, J
    Rodriguez, D
    Courter, S
    BLOOD, 1998, 92 (10) : 356A - 356A
  • [16] Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A
    Calvez, Thierry
    Chambost, Herve
    Claeyssens-Donadel, Segolene
    d'Oiron, Roseline
    Goulet, Veronique
    Guillet, Benoit
    Heritier, Virginie
    Milien, Vanessa
    Rothschild, Chantal
    Roussel-Robert, Valerie
    Vinciguerra, Christine
    Goudemand, Jenny
    BLOOD, 2014, 124 (23) : 3398 - 3408
  • [17] The type of products (plasmatic vs recombinant) may exert an influence on FVIII inhibitor incidence in previously untreated severe hemophilia a patients (PUPs).
    Goudemand, J
    Rothschild, C
    Demiguel, V
    Lambert, T
    Calvez, T
    BLOOD, 2003, 102 (11) : 798A - 798A
  • [18] US Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics
    Carpenter, Shannon L.
    Chandler, Martin
    Guerrera, Michael F.
    Malec, Lynn
    Manuel, Matthew
    Recht, Michael
    Reiss, Ulrike
    Sidonio, Robert F., Jr.
    Tarango, Cristina
    Van den Berg, Marijke
    Wang, Michael
    Thornburg, Courtney D.
    BLOOD, 2022, 140
  • [19] Recombinant factor IX (rFIX) treatment of previously untreated patients (PUPs) with severe or moderately severe hemophilia B.
    Shapiro, A
    Abshire, T
    Kisker, T
    Lee, C
    Pasi, J
    Pollmann, H
    Nguyen, K
    Nissen, S
    BLOOD, 2000, 96 (11) : 264A - 265A
  • [20] Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia B.
    Shapiro, A
    Pasi, KJ
    Abshire, T
    Kisker, CT
    Cohen, A
    Goddard, J
    Courter, S
    BLOOD, 1997, 90 (10) : 684 - 684
12345